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EQUINE DISEASE MODEL FOR
HERPESVIRUS NEUROLOGIC DISEASE
AND USES THEREOF

tics," Equine Vet J33:191-196 (2001); M. J. Studdert et al.,
"Outbreak of equine herpesvirus type 1 myeloencephalitis:
new insights from virus identification by PCR and the
application of an EHV-1-specific antibody detection
ELISA," Vet Rec 153:417-423 (2003); S. M. ReedandR. E.
Toribio, "Equine herpesvirus 1 and 4," Vet Clin North Am
Equine Pract 20:631-642 (2004); T. A. Jackson and J. W.
Kendrick, "Paralysis of horses associated with equine herpesvirus 1 infection," J Amer Vet Med Assoc 158:1351-1357
(1971 ); K. M. Charlton et al., "Meningoencephalomyelitis in
horses associated with equine herpesvirus 1 infection," Vet
Pathol 13:59-68 (1976); P. B. Little and J. Thorsen, "Disseminated necrotizing myeloencephalitis: a herpes-associated neurological disease of horses," Vet Pathol l3:l6l-l 7l
(1976); H. Platt et al., "Pathological observations on an
outbreak of paralysis in broodmares," Equine Vet J 12:118126 (1980); R. S. Greenwood and A. B. Simpson, "Clinical
report of a paralytic syndrome affecting stallions, mares and
foals on a Thoroughbred studfarm," Equine Vet J 12:113-117
(1980); K. E. Whitwell and A. S. Blunden, "Pathological
findings in horses dying during an outbreak of the paralytic
form of Equid herpesvirus type 1 (EHV-1) infection,"
Equine Vet J24:13-19 (1992); C. W. Kohn and W.R. Fenner,
"Equine herpes myeloencephalopathy," Vet Clin N Am:
Equine Pract 3:405-419 (1987)).
Although the specific innnune mechanisms required for
control of EHV-1 neurologic disease are largely not established, a well known innnunoeffector mechanism for controlling the level of cell-associated viremia of other herpesviruses is cytotoxic T lymphocytes (CTL) (A. M. Arvin,
"Cell-mediated innnunity to varicella-zoster virus," J Infect
Dis 166:35-41 (1992); S. Martin et al., "Herpes simplex
virus type 1 specific cytotoxic T lymphocytes recognize
virus nonstructural proteins,"J Viral 62:2265-2273 (1988)).
Later investigations of Kydd et al. demonstrated that resistance to EHV-1 abortion in ponies was associated with high
frequencies of pre-exposure, EHV-1 specific CTLp in the
blood circulation (J. H. Kydd et al., "Pre-infection frequencies of equine herpesvirus-1 specific, cytotoxic T lymphocytes Fcorrelate with protection against abortion following
experimental infection of pregnant mares," Vet Immunol &
Immunopathol 96:207-217 (2003)). However, the Kydd et
al. study dealt solely with abortion as a disease outcome of
EHV-1 infection and did not address the neurological manifestation of EHV-1 infection.
Recent molecular characterization of EHV-1 isolates
recovered from outbreaks of neurologic disease has revealed
that the majority of isolates are variant strains of the virus
that possess an adenine (A) to guanine (G) base substitution
at position 2254 of the gene that encodes the viral DNA
polymerase (open reading frame #30; ORF30) (J. Nugent et
al., "Analysis of equine herpesvirus type 1 strain variation
reveals a point mutation of the DNA polymerase strongly
associated with neuropathogenic versus non-neuropathogenic disease outbreaks," J Viral 80:4047-4060 (2006)). It
has been postulated that this unique mutation in the catalytic
subunit of the viral replication complex endows such virus
strains with an enhanced replicative vigor that increases the
number and severity of lesions of necrotizing vasculitis in
the blood vessels of the central nervous system of the
infected horse (K. E. Whitwell and A. S. Blunden, "Pathological findings in horses dying during an outbreak of the
paralytic form of Equid herpesvirus type 1 (EHV-1) infection," Equine Vet J 24:13-19 (1992); G. P. Allen and C. C.
Breadthnach, "Quantification by real-time PCR of the magnitude and duration of leukocyte-associated viraemia in

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application connnences the national stage under 35
U.S.C. §371 of PCT International Application No. PCT/
US2009/004409, filed on Jul. 29, 2009, which claims the
priority benefit of U.S. Provisional Application No. 61/137,
412, filed on Jul. 30, 2008. The prior applications are
incorporated herein by reference in their entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
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AGREEMENT
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The material on a single compact disc containing a
Sequence Listing file provided in this application is incorporated by reference thereto.
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BACKGROUND OF THE INVENTION
Field of the Invention
The present invention concerns quantifiable risk factors
for the post-exposure development of equine herpesvirus-1
neurological disease and their use to provide a new equine
experimental disease model for evaluating and developing
effective vaccines for the protection of horses against equine
herpesvirus-1 neurological disease. The invention further
relates to a new live, attenuated vaccine and its use to
prevent neurological disease caused by equine herpesvirus1.
Description of Related Art
All patents and publications cited in this specification are
hereby incorporated by reference in their entirety.
Epizootics of neurological disease caused by equine herpesvirus-1 (EHV-1) have been reported with increasing
frequency in the United States during the past several years
(United States Department of Agriculture, "Equine herpes
virus myeloencephalopathy: A potentially emerging disease," USDA: APHIS: Veterinary Services: Centers for
Epidemiology and Animal Health, Center for Emerging
Issues Information Sheet, 2007). Characterized by high
neurologic morbidity and case fatality rates, resistance to
prevention by vaccination, and the ability to affect horses of
all breeds and ages, EHV-1 myeloencephalopathy has the
potential for causing catastrophic losses to both the welfare
of horses and the economy of equine-based businesses (M.
T. Donaldson and C. R. Sweeney, "Equine herpes myeloencephalopathy," Compend Cantin Edu Pract Vet 19:864871 (1997); W. D. Wilson, "Equine herpesvirus 1 myeloencephalopathy," Vet Clin North Am Equine Pract 13:53-72
(1997); R. W. Henninger et al., "Epidemic neurologic disease due to equine herpesvirus-1 at a university equestrian
center," J Vet Intern Med 21:157-165 (2007); C. van Maanen
et al., "Neurological disease associated with EHV-1 infection in a riding school: clinical and virological characteris-
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horses infected with neuropathogenic versus non-neuropathogenic strains of equine herpesvirus-1," Equine Vet J
38:252-257 (2006)).
Concern has been voiced that genetic change in the herpes
viral agent with a concomitant increase in its virulence is
resulting in the neurological manifestation of EHV-1 infection that is increasing in incidence, morbidity and case
fatality rates (United States Department of Agriculture,
"Equine herpes virus myeloencephalopathy: A potentially
emerging disease," USDA: APHIS: Veterinary Services:
Centers for Epidemiology and Animal Health, Center for
Emerging Issues Information Sheet, 2007). The increase in
incidence of the high-mortality herpesviral neurological
disease of horses that is not protected against by currently
marketed vaccines has fueled genuine concerns about its
effect on the future economic prosperity of the U.S. horse
industry. Of particular alarm to the equine industry is its
recent targeting of horses in riding/boarding stables and of
young horses assembled at race track venues for training and
racing, with consequent high mortality rates and severe
economic losses to the boarding and racing sectors of the
industry. Although efforts to develop a more effective,
second-generation vaccine against the neurologic herpesvirus disease are underway by several vaccine manufacturers,
no equine disease model exists for assessing the effectiveness of such experimental vaccines.
In fact, a practical neurological disease model has never
been created, either in connection with standard laboratory
mice, rats or guinea pigs where the neurological effects of
EHV-1 infection can never develop, or even from prior
equine studies of EHV-1 in horses or ponies. Earlier challenge studies, including those reported in the published
paper by T. O'Neill et al., "Determination of equid herpesvirus I-specific, CDS+, cytotoxic T lymphocyte precursor
frequencies in ponies," Vet Immunol & Immunopathol
70:43-54 (1999), did not address the neurological manifestation of EHV-1 infection or disease. Since the oldest group
of 9-year-old ponies in that 1999 study showed frequencies
of EHV-1 specific CTLp that were high before experimental
infection, it was concluded by the co-authors that high CTLp
frequency may correlate with immunity to EHV-1. Furthermore, the ponies never reached the point where they presented any neurological signs. Their blood analysis and
physical characteristics are oflimited value, consequently, in
determining the factors giving rise to neurological disease,
the traits of a neurological disease model or the criteria
useful in predicting development of neurological disease.
Previously, vaccination strategies have focused on the
well-known murine model of EHV-1 infection in which the
efficacy and safety of the EHV-1 vaccines are initially tested
in vivo in mice rather than directly in horses ( see, for
example, A. R. Frampton et al., "Meningoencephalitis in
mice infected with an equine herpesvirus 1 strain KyA
recombinant expressing glycoprotein I and glycoprotein E,"
Virus genes 29(1):9-17 (August 2004); C. F. Colle et al.,
"Equine herpesvirus-1 strain KyA, a candidate vaccine
strain, reduces viral titers in mice challenged with a pathogenic strain, RacL," Virus Research 43(2):111-124 (August
1996); T. Kondo et al., "A protective effect of epidermal
powder immunization in a mouse model of equine herpesvirus-I infection," Virology 318(1):414-419 (January 2004);
C. Walker et al., "Comparison of the pathogenesis of acute
equine herpesvirus 1 (EHV-1) infection in the horse and the
mouse model: a review," Veterinary Microbiology 68(1):313 (August 1999); K. M. Ruitenberg et al., "DNA-mediated
immunization with glycoprotein D of equine herpesvirus 1
(EHV-1) in a murine model of EHV-1 respiratory infection"

Vaccine 17(3): 237-244 (February 1999); P. A. M. van
Woensel et al., "A mouse model for testing the pathogenicity
of equine herpes virus-I strains," Journal of Virological
Methods 54(1):39-49 (July 1995); M. K. Baxi et al.,
"Molecular studies of the acute infection, latency and reactivation of equine herpesvirus-1 (EHV-1) in the mouse
model," Virus Research 40(1):33-45 (January 1996).
While the murine model has served its purpose as a model
for simple EHV-1 infections characterized by clinical signs
such as pyrexia (abnormally elevated body temperature) or
loss of body weight, the mouse as an experimental model for
studying the neurological disease and efficacious vaccine
candidates in large horses has several drawbacks. First of all,
the EHV-1 infection in the mouse never can progress to
express the same breadth of neurological signs that plague
the natural host, namely, horses, thus failing to provide a
complete picture as a viral vaccine candidate model to
permit adequate vaccination strategies in horses. For
instance, myeloencephalopathic disease like that exhibited
by herpesvirus infected horses does not develop in the
experimental mouse model of herpesvirus disease. Secondly, a major adverse effect of infection in pregnant mares
is the induction of spontaneous infectious abortions, which
cannot be duplicated or investigated in the vaccination
studies run in the classic murine model. Thirdly, without a
solid understanding of the clinical signs and progression of
the EHV-1 disease in horses, the vaccine candidates will not
have broad applicability and activity to prevent more serious
neurologic signs than simple infections caused by the single
etiological agent in the mouse. More research on the progression of the disease in the natural host is necessary
beyond the bare minimal effects from infection in the mouse.
Fourthly, the detection of new mutant equine herpesviruses
has further limited the application of the murine model as a
practical animal model for vaccine purposes.
Eventually, final testing of the safety and efficacy of the
virus strains will take place in vivo in horses. Equine
vaccines, which are commercially available and described in
the art, are subsequently tested on horses, but typically only
after the initial efficacy and safety studies in the classic
murine model that leave a wide gap in vaccination data. For
a case directly on point, the horse vaccines comprising a
mutant EHV-1 or EHV-4 virus disclosed in U.S. Pat. No.
7,060,282 are shown as being conventionally tested first
through in vivo studies in laboratory mice. The patentees
note the limitations of using the standard murine model to
confirm protective activity in horses. They indicate that
while pathogenicity of individual EHV-1 strains can be
correlated from the mouse model to the behavior in the
natural equine host, more conclusive proof is obtained only
from vaccination trials in horses. Patentees further complain
that the level of protection against challenge infection and
ultimately in preventing abortion in pregnant mares can only
be established in the target animal and, thus, the initial
murine testing is of limited value in the final analysis.
There is a definite art-recognized problem with the classic
mouse model that the present invention solves by developing the first equine disease model for the successful reproduction of herpesvirus-1 neurological disease in the horse.
It is therefore an important object of the present invention
to provide a unique equine experimental disease model that
is useful for evaluating and developing safe and effective
vaccines in the protection of horses against equine herpesvirus infections and, more specifically, against equine herpesvirus-1 neurological disease.
It is a further important object of the present invention to
identify the parameters in equine herpesvirus inoculated
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horses that are highly correlated with post-inoculation development of clinical disease and particularly to find the
quantifiable risk factors that are directly associated with the
development of clinical neurological signs in horses exposed
to equine herpesvirus-1.
It is another important object of the invention to find an
effective modified live, virus vaccine that protects horses
against neurological disease due to infection caused by
equine herpesvirus-1. While presently known EHV-1 vaccines that claim protection against neurologic disease as well
as respiratory disease and abortion are largely based on
inactivated viruses (see, for example, U.S. Pat. Nos. 7,323,
178 and 7,226,604), it is art-recognized that live and attenuated viral vaccines, as a general rule, can induce a better
immune response. Therefore, this goal of the present invention is to provide a new and improved live, attenuated
vaccine formulation that stimulates a protective immune
response against neurologic disease due to equine herpesvirus-1.
Further purposes and objects of the present invention will
appear as the specification proceeds.
The foregoing objects are accomplished by providing a
novel equine disease model, the determination of the quantifiable risk factors for the post-exposure development of
equine herpesvirus-1 neurological disease and a unique
equine herpesvirus-1 vaccine as described herein.

FIG. 1 illustrates the relationships among peak magnitude
ofviremia, pre-infection CTLp frequency and development
of clinical neurologic disease in 24 horses following exposure to neuropathogenic EHV-1. White circles represent
horses with neurologic signs while the black circles stand for
the horses without neurologic signs. EHV-1 DNA present in
equine peripheral blood mononuclear cells (PBMC) was
quantified by real-time qPCR and the amount expressed as
log 10 of the fold-difference relative to that present in a
reference calibrator PBMC DNA (relative quantification;
RQ). Determination in equine PBMC of the frequency of
CTL precursors (CTLp) specific for EHV-1 was done by
limiting dilution analysis.
FIG. 2 shows the mean±SE daily values for magnitude of
leukocyte-associated (PBMC-associated) viremia in 12
young (<15 years, shown by darkly shaded area) and 12 old
(>20 years, shown by lightly shaded area) horses following
intranasal inoculation with a neuropathogenic strain of
EHV-1. EHV-1 DNA present in equine peripheral blood
mononuclear cells (PBMC) was quantified by real-time
qPCR and the amount expressed as the fold-difference
relative to that present in a reference calibrator PBMC DNA
(relative quantification; RQ). The results are presented as an
"area-fill plot" to visually illustrate the two-dimensional
character (magnitude and duration) of EHV-1 viremia, in
which the total viral load experienced by the infected horse
is proportional to the shaded area beneath each curve.
Standard errors of the mean RQ values for each age group
of 12 horses on each sampling day post-inoculation are
indicated by the error bars. The differences between the two
age groups of mares in their mean magnitude of EHV-1
viremia are significant at P=s0.05 for post-inoculation days
4 through 10.
FIG. 3 shows a comparison of the mean±SE daily magnitude of leukocyte-associated (PBMC-associated) viremia
in 24 elderly horses (>20 years) following inoculation with
either an ORF30 A 2254 strain (T262, the wild-type EHV-1
strain shown by darkly shaded area; n=12 horses) or an
ORF30 G 2254 strain (T953, the mutant EHV-1 strain shown
by lightly shaded area; n=12 horses) ofEHV-1. EHV-1 DNA
present in equine peripheral blood mononuclear cells
(PBMC) was quantified by real-time qPCR, and the amount
was expressed as log 10 of the fold-difference relative to that
present in a reference calibrator PBMC DNA (relative
quantification; RQ). The results are presented as an "area-fill
plot" to visually illustrate the two-dimensional character
(magnitude and duration) of EHV-1 viremia, in which the
total viral load inflicted upon the infected horse is proportional to the shaded area beneath each curve. Standard errors
of the mean log 10 RQ values for each treatment group of 12
horses are indicated by the error bars. The differences in the
mean magnitude of EHV-1 viremia resulting from inoculation with the two genetic strains of EHV-1 are significant at
P=s0.05 for post-inoculation days 4 through 12.
FIG. 4 illustrates the analysis of data for relationship
between pre-infection serum neutralizing antibody (SNA)
titer against EHV-1 and either peak magnitude of EHV-1
viremia or development of clinical neurologic disease in 24
horses following exposure to neuropathogenic EHV-1.
White circles represent horses with neurologic signs while
the black circles stand for the horses without neurologic
signs. EHV-1 DNA present in equine peripheral blood
mononuclear cells (PBMC) was quantified by real-time
qPCR and the amount expressed as log 10 of the folddifference relative to that present in a reference calibrator
PBMC DNA (relative quantification; RQ). Determination of
serum levels of neutralizing antibodies specific for EHV-1
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BRIEF SUMMARY OF THE INVENTION
The present invention relates to a new disease model for
equine herpesvirus-1 neurological disease comprising a
horse possessing the following quantifiable risk factors that
highly correlate with the post-exposure development of
equine herpesvirus-1 neurological disease: (1) the magnitude of post-infection, systemically circulating EHV-1
infected leukocytes (viremic load); (2) the pre-exposure
frequency of circulating cytotoxic T lymphocyte precursors
(CTLp) specific for EHV-1; (3) the ORF30-2254 genotype
of the infecting strain of EHV-1; and (4) age category of the
exposed horse. Also embraced by the present invention is the
previously unknown identification of these risk factors that
directly correlate to the development of clinical signs of
neurological disease in horses exposed to equine herpesvirus-1 and making novel use of such identification in a new
method of quantifying the risk factors and predicting the
development of clinical neurologic signs of equine herpesvirus-1 neurological disease. Of the identified risk factors,
infection by an ORF30 G 2254 strain of EHV-1 has the
strongest association with the probability of clinical progression of the herpesviral infection to clinically overt
neurological disease. Important embodiments of the invention are thus drawn to the in vivo equine disease models
wherein the horse is experimentally infected, typically
through intranasal administration, with a neuropathogenic
strain of equine herpesvirus or a mutant thereof, such as the
ORF30 G 2254 strain ofEHV-1, in which the horse has a low
pre-exposure level of herpesvirus-specific CTL precursors
and/or is about 20 years of age or older as well as the method
of preparing the in vivo equine disease model for EHV-1
neurological disease. An additional embodiment of the
invention employs a live, attenuated strain of equine herpesvirus or a mutant thereof as the antigen in a modified
vaccine and its use to protect horses against neurological
disease due to infection caused by equine herpesvirus-1.
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was done by a microneutralization assay. The correlation
coefficient, r, between the two plotted variables is -0.31. The
statistical probability (P value) that no linear relationship
exists between pre-exposure SNA titer and magnitude of
post-exposure EHV-1 viremia is 0.144.

neurological disease of horses. The innovativeness of the
invention is found in the discovery of the quantifiable risk
factors that permit the selection of the experimental horse
subjects and the challenge strain of herpesvirus that allow
reproduction of the neurological disease in a high proportion
of virus-inoculated horses. In view of this discovery, the
present invention further embraces a new method of quantifying risk factors and predicting the development of clinical neurologic signs of equine herpesvirus-1 neurological
disease in a horse. The unique method comprises the two
steps of: (a) determining the pre-infection CTLp frequency
to be less than approximately 40 EHV-1 specific CTLp per
106 (i.e., per million) PBMC(equine peripheral blood mononuclear cells) and/ or determining the age of the horse to be
approximately 20 years of age or older; and (b) determining
the post-infection viremic load following exposure to
EHV-1 to be approximately 10-fold or more over the viremic
load present in horses following exposure to a non-neuropathogenic strain of EHV-1. Desirably, step (a) embraces
determining the pre-infection CTLp frequency to be less
than approximately 20 EHV-1 specific CTLp per 10 6 PBMC
and, more desirably, determining the pre-infection CTLp
frequency to be less than approximately 10 EHV-1 specific
CTLp per 10 6 PBMC while step (b) independently encompasses determining the post-infection viremic load following exposure to EHV-1 to be approximately 100-fold or
more greater than the viremic load present in horses following exposure to a non-neuropathogenic strain ofEHV-1 and,
even more desirably, determining the post-infection viremic
load following exposure to EHV-1 to be greater than 1000fold higher than the viremic load present in horses following
exposure to a non-neuropathogenic strain of EHV-1.
Up until the present invention, the risk factors associated
with EHV-1-induced myeloencephalopathy in horses had
not yet been fully investigated. In addition, certain researchers provided incorrect conclusions regarding the factors
giving rise to EHV-1 disease, which clouded the animal
health issues. This invention represents a real advancement
in the veterinary arts since the parameters in EHV-1 inoculated horses that are highly correlated with post-inoculation
presentation of clinical neurological disease are now fully
identified.
Although the underlying basis for predicting which horses
will make effective experimental subjects is seen to be the
magnitude of CTLp circulating in the blood, it is also now
unexpectedly found that the aged horses coincidentally but
almost uniformly exhibit low levels of CTLp as a result of
the waning immune system that accompanies aging. Consequently, the invention also includes the bare determination
of the horse age, in particular, about 20 years old or more,
as a valid and sole criterion for predicting and selecting
experimental subjects for the disease model.
Insofar as the age of the horse disease model is concerned,
the present invention further embraces the use of foals,
typically as young as roughly one week old to just about one
year old in age, in which low pre-infection levels ofEHV-1
specific CTL precursors are created and induced by suitable
immune-suppressing agents. While a horse of any age can be
immune-suppressed, the foal, which does not yet exhibit low
levels of CTLp naturally, can be immunosuppressed desirably with conventional immunosuppressing drugs to impair
the CTL function. The immune-suppressing agents useful in
the present invention include, but are not limited to, antimetabolites such as azathioprine, mycophenolate mofetil,
etc.; corticosteroids, calcineurin inhibitors such as
cyclosporine, tacrolimus, etc.; sirolimus; polyclonal antibody therapy; monoclonal antibody therapy using, for

5

DETAILED DESCRIPTION OF THE
INVENTION
In accord with the present invention, there is provided a
unique equine experimental disease model of equine herpesvirus-1 (hereinafter referred to as "EHV-1 ") infection
and neurological disease, that is highly useful for the evaluation and the development of safe and efficacious vaccines
for the protection of horses against debilitating neurological
disease. The innovative neurological disease model of
EHV-1 is defined and the disease is reproduced in horses for
the first time. Understanding the pathogenesis in horses and
quantifying the risk factors for the post-exposure incidence
of EHV-1 disease permit the valuable development of vaccine strategies that can target the specific signs of disease. As
a result of this invention, it is now possible to considerably
improve and to preferentially target the mode of action of
EHV-1 vaccine candidates to obtain a more reproducible and
reliable outcome than previously achievable.
An important embodiment of this invention encompasses
the particular in vivo equine disease model in which an
experimental horse having a low pre-exposure level of
herpesvirus-specific CTL precursors and/or is about 20 years
of age or older is challenged with a neuropathogenic strain
of equine herpesvirus or a mutant thereof. Distinguishing
from natural infections, the horse of the present invention is
inoculated (i.e., artificially infected) by a person who gives
an effective challenge dose to the horse, typically by intranasal administration of EHV-1 although other standard
routes of administering the viral agent such as intrarectal,
oral, intramuscular, intradermal, subcutaneous and the like
are possible. The amount of an effective challenge dose,
which is the quantity of EHV-1 sufficient to cause signs of
infection, can be readily determined and titrated through
routine testing in horses. The neuropathogenic strain of
EHV-1 or the mutant thereof includes, but is not limited to,
the ORF30 G 2254 strain ofEHV-1 such as T953, Army 183,
Ab4, etc. and others known to those of ordinary skill in the
veterinary viral art. Preferably, the experimental disease
model has been created by intranasal inoculation with an
effective challenge dose of the neuropathogenic ORF30
G 2254 strain of EHV-1 and the horse possesses high levels of
post-infection, leukocyte-associated viremia. Of particular
benefit as a highly desirable experimental model of this
invention is the in vivo equine disease model for EHV-1
neurological disease that develops or presents with clinical
signs of myeloencephalopathy.
Another important embodiment of the present invention
relates to the method of preparing the in vivo equine disease
model for EHV-1 neurological disease which comprises
obtaining a horse that possesses low pre-infection levels of
EHV-1 specific CTL precursors and/or is roughly 20 years of
age or older and inoculating the horse intranasally with an
effective challenge dose of a neuropathogenic strain of
EHV-1, preferably the ORF30 G 2254 strain of EHV-1 such
as, for example, the T953, Army 183, Ab4 strains ofEHV-1,
etc.
Commercial vaccine developers can use the reproducible,
neurologic disease model for equine herpesvirus myeloencephalopathy for assessment of the protective efficacy of
their candidate antiviral vaccines against the herpesviral
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example, OKT3 or daclizumab and basiliximab; and the
like. Preferably, the immunosuppression is produced by
dexamethasone or another comparable corticosteroid.
Inducing immunosuppression can be achieved by any
standard technique known in the art (see, e.g., N. R. Barshes
et al., "Pharmacologic Immunosuppression," Frontiers in
Bioscience 9:411-420 (Jan. 1, 2004); T. J. Cutler et al.,
"Immunosuppression against Sarcocystis neurona in normal
and dexamethasone-treated horses challenged with S. neurona sporocysts," Veterinary Parasitology 95:197-210
(2001); D. B. Tumas et al., "Corticosteroid immunosuppression and monoclonal antibody-mediated CD5+T lymphocyte depletion in normal and equine infectious anaemia
virus-carrier horses," J Gen Virology 75:959-968 (1994)) By
way of an example relevant to the present invention, a foal
less than one year old in age is injected intravenously with
1 mg/kg of dexamethasone per body weight per day for
approximately nine days to induce immunosuppression
where the CTL function becomes impaired. About four to
five days after treatment with dexamethasone is completed,
the young horse possessing the impaired CTL function is
then challenged with a suitable infecting amount of a
neuropathogenic strain of EHV-1 strain to create the disease
model of this invention.
Demonstration of characteristics whose quantitative levels are so highly correlated with development of postinfection EHV-1 neurological disease in the horse would be
useful to the veterinary industry in the identification of
practical targets for the action of future EHV-1 vaccines and
antiviral drugs. As such, the primary goal met by the present
invention is the recognition of parameters that are statistically associated with development of post-exposure, EHV-1
neurological disease; i.e., to identify disease risk factors in
EHV-1 inoculated horses that are highly correlated with
post-inoculation development of clinical neurologic disease.
Identification of such neurologic risk-associated parameters
gives definitive and quantifiable prognostic indicators for
development of clinical EHV-1 myeloencephalopathy following infection by the herpesvirus.
A secondary goal satisfied by the current invention is the
clarification of the immunological mechanisms that horses
use for controlling the magnitude of EHV-1 cell-associated
viremia and its vasculitis-mediated sequelae of ischemic
damage to the equine central nervous system (CNS). The
latter information provides valuable insight into the types of
immunologic effector responses required to be elicited by
vaccines for successful immunoprevention of EHV-1 paralytic disease and serves as reliable, in vitro immune correlates of vaccine protection against the neurologic disease.
As a further aspect of the present invention, it has been
observed that the risk of developing the clinical neurologic
signs is determined according to an equation y=a+bx
wherein y is the peak viremic load, a=2.97, b=-0.027 and
the variable x is the pre-infection CTLp frequency. By this
equation, a linear relationship or a correlation coefficient
statistic r between the two numerical variables ofy and xis
-0.79 is indicative of the risk of developing the clinical
neurologic signs.
Illustrated in depth in the below examples, thirty-six
adult, mixed breed, horse mares are inoculated intranasally
with live, virulent strains of EHV-1. Blood samples, which
are collected daily from the thirty-six experimental horses
before and after challenge inoculation with either nonneuropathogenic (ORF30 A 2254) or neuropathogenic
(ORF30 G 2254) strains of EHV-1, are analyzed for quantitative levels of leukocyte-associated viremia (measured by
real-time qPCR), serum neutralizing antibody (SNA; mea-

sured by micro-neutralization test), and EHV-1-specific
cytotoxic T lymphocyte precursors (CTLp; measured by
limiting dilution analysis of chromium-51 release assay
results). The data are examined for statistically significant
associations between values of the measured parameters and
the occurrence of post-challenge clinical neurologic disease
in the experimentally infected horses. Correlations between
age-category or breed of the EHV-1 inoculated horses and
post-exposure development of neurologic disease are also
examined.
The results of the challenge studies show that nine of the
thirty-six EHV-1 inoculated horses develop clinical signs of
central nervous system disease (ataxia, hindlimb paresis or
paralysis, bladder atony, and/or recumbency). Post-exposure
development of clinically apparent neurologic deficits in the
study horses is positively correlated with infection by a
neuropathogenic strain ofEHV-1, advanced age (>20 years),
elevated post-exposure viremic load, and a low pre-exposure
level of virus-specific CTLp. Unexpectedly, the pre-infection serum neutralizing antibody titer has the least correlation to development of disease after exposure to EHV-1. In
addition, no significant correlation is observed between
horse breed and the post-infection development of neurologic signs.
Also surprising is the finding that the category of horse at
greatest risk for development of myeloencephalopathy following infection by EHV-1 is the elderly horse (>20 years)
exposed to a neuropathogenic strain of the virus (ORF30
G 2254) and possessing low pre-infection levels of EHV-1
specific CTL precursors and high levels of post-infection,
leukocyte-associated viremia. By contrast, horses possessing high levels of pre-existing, EHV-1 specific CTL precursors, regardless of age, strain of virus, or SNA titer, are more
likely to control the magnitude of post-infection, leukocyteassociated viremia and the subsequent development of
EHV-1 neurologic disease. These observations serve to
identify CTLp as one of the critical immune requirements
for protective immunity to EHV-1 induced myeloencephalopathy. The importance of achieving high levels of vaccine
induced CTL immunity in groups of horses at high risk for
exposure to neuropathogenic strains of EHV-1 is clearly
indicated from the results of these studies.
The results establish a strong association (P=<0.01 by
Fisher's exact test) between the ORF30 genotype (A2254 or
G 2254) of the infecting strain of EHV-1 and the subsequent
risk for development of clinically apparent neurologic deficits in the infected horse. While none of 12 mares inoculated
with an ORF30 A 2254 EHV-1 strain exhibit neurologic signs,
8 of 12 age- and gender-matched horses inoculated with an
ORF30 G 2254 strain of EHV-1 develop severe neurologic
complications, with euthanasia required in 6 of the 8 neurologically affected animals. Of the several potential risk
factors evaluated in this study, infection by an ORF30 G 2254
strain of EHV-1 is found to be most strongly associated with
the probability of clinical progression of the viral infection
to clinically overt neurological disease.
The data also establish a strong association (P=0.009 by
Fisher's exact test) of the clinical progression of EHV-1
infection to neurological disease with the age-category of
the inoculated horse. The risk for development of EHV-1
paralytic disease following exposure to a neuropathogenic
genotype of the virus was 8-fold greater in elderly horses
(>20 years) than in young to middle age adult horses (<15
years). Comparison of the post-inoculation viremic load of
EHV-1 infected leukocytes present in the 12 elderly and 12
young experimental horses revealed that the mean, peak
magnitude of cell-associated viremia was 100-fold greater in

5

10

15

20

25

30

35

40

45

50

55

60

65

US 9,642,908 B2
11

12

the elderly horse group. Thus, the quantitative load of
circulating virus that follows infection by EHV-1 was
defined as a major risk factor (P=<0.001 by analysis of
variance test) for post-exposure development of EHV-1
CNS disease. The relatively greater susceptibility of elderly
horses for development of EHV-1 neurological disease provides an experimental, neurologic disease model which may
prove useful for assessment of vaccine efficacy against
EHV-1 myeloencephalopathy.
To investigate the role of memory CTL specific for
neuropathogenic strains of EHV-1 as effectors for reducing
the magnitude of post-infection viremia, quantitative estimates of the pre-exposure frequency of EHV-1 specific CTL
precursors (CTLp) in the experimental horses are determined herein below by limiting dilution analysis of Cr-51
release assays. The results in connection with the present
invention identify pre-exposure frequency ofEHV-1 specific
CTLp as a strong correlate (regression correlation coefficient=-0.71) of the post-infection magnitude of cell-associated viremia and also as a statistically significant (P=<0.01
by logistic regression analysis) correlate of protective immunity against the myeloencephalopathy caused by infection of
horses with neuropathogenic strains of EHV-1. These findings suggest a role of CTL immune responses of the horse
in maintaining immunological control of EHV-1 viremia.
Such results support the view that a critical-mass reservoir
of circulating memory CTL, in place at the moment and
location of virus exposure and capable of being activated
into functional CTL with specific cytolytic activity against
EHV-1, is required for controlling EHV-1 neurological disease. In order to achieve protective efficacy against EHV-1
myeloencephalopathy by vaccination, it follows that the
vaccines must be able to drive the equine immune response
toward the production of such cytolytically functional,
effector CTL.
On the other hand, it is now discovered that the level of
antibodies present prior to virus inoculation surprisingly
does not correlate with protection against challenge with
neuropathogenic EHV-1. After performing measurements of
EHV-1 specific SNA present in the experimental horses at
the time of virus inoculation, the results failed to reveal any
significant relationship between pre-exposure SNA titer and
the magnitude of post-infection viremia. The intracellular
location of EHV-1 during most of its infection cycle within
the horse may limit the effectiveness of virus neutralizing
antibody in controlling the level of cell-associated EHV-1
vJremia.
In sum, of the six neurologic risks evaluated for relation
to the presentation of the disease entity caused by EHV-1
((1) the magnitude of post-infection, systemically circulating EHV-1 infected leukocytes (viremic load); (2) the preexposure frequency of circulating cytotoxic T lymphocyte
precursors (CTLp) specific for EHV-1; (3) the pre-infection
titer of serum neutralizing antibody to EHV-1; (4) the
ORF30-2254 genotype of the infecting strain of EHV-1; (5)
breed of horse; and (6) age category of the exposed horse),
it is determined that the pre-infection titer of serum neutralizing antibody to EHV-1 and the breed of horse have no
correlation of the progression of EHV-1 infection to neurological disease. Surprisingly, infection by an ORF30 G 2254
strain of EHV-1 is determined to be most strongly connected
to the probability of progression of the viral infection to
clinically overt neurological disease.
A practical advantage of the present invention is found in
the novel use of the experimental horse model to evaluate
the efficacy of broad-spectrum candidate vaccines for the
protection of horses against EHV-1 that not only protects

against viral infection but also protects against the debilitating and often fatal EHV-1 myeloencephalopathy. A disturbing characteristic of the emerging hypervirulent, neuropathogenic mutants of equine herpesvirus-1 is their inability
to be curtailed by the level or type of immunity engendered
by current-generation vaccines for EHV-1. The development
of second-generation vaccines against the mutant herpesvirus requires an equine neurologic disease vaccination-challenge model in which candidate vaccines can be tested for
protective efficacy against EHV-1 myeloencephalopathy.
The real benefit of the present invention can be readily seen
in the development and validation of the unique EHV-1
neurologic disease model in horses for practical use in
vaccination-challenge studies for the evaluation of the neurologic protective efficacy of candidate vaccines.
Quantitative parameters (e.g., viral genotype, age, and
levels ofviremia and antiviral cellular immunity (CTLp )) in
EHV-1 inoculated horses, that are highly correlated with
post-inoculation development of neurologic disease and
identified herein, serve to define the composition of the
experimental disease model of the present invention. Contributing to the high rate of experimentally produced EHV-1
neurologic disease in virus-challenged horses are the use of
(1) horses with low levels of antiviral cellular immunity as
subjects for vaccination and challenge, and (2) a particularly
neuropathogenic challenge strain ofEHV-1 (a Findlay 2003
isolate that was originally obtained from an outbreak of
EHV-1 disease among 135 horses stabled at the University
of Findlay Equestrian Center, Findlay, Ohio and subsequently described in R. W. Henninger et al., "Epidemic
neurologic disease due to equine herpesvirus-1 at a university equestrian center," J Vet Intern Med 21: 157-165 (2007)).
The presently developed EHV-1 neurologic disease model is
evaluated by studies that determine a significant level of
immune protection against EHV-1 neurologic disease is
unexpectedly established in horses by vaccination with a
live, non-neuropathogenic strain of EHV-1.
A further important embodiment of the present invention
is drawn to novel live, attenuated viral vaccines containing
a non-neuropathogenic strain of EHV-1 having the ORF30
A 2254 genotype, for example, the T262 strain or a neuropathogenic strain ofEHV-1 having the ORF30 G 2254 genotype such as the T953, Army 183 or Ab4 strain, as the viral
antigen alone or in combination with one or more other
antigens and a method of administering the vaccine to
prevent or to minimize the effects of viral infection that can
progress to neurologic disease as well as to protect against
development of neurologic disease including myeloencephalopathy caused by the neuropathogenic viruses.
Advantageously, the new method protects horses in need
of protection against neurologic disease due to neuropathogenic EHV-1 by administering to the horse an immunologically effective amount of the vaccine according to the
invention. The immunologically effective amount or the
immunogenic amount that inoculates the horse can be easily
determined or readily titrated by routine testing. An effective
amount is one in which a sufficient immunological response
to the vaccine is attained to protect the horse exposed to the
EHV-1 virus which causes neurologic disease and myeloencephalopathy. Preferably, the horse is protected to an
extent in which one to all of the adverse physiological signs
or effects of the neurologic viral disease are significantly
reduced, ameliorated or totally prevented.
The foal's immunization schedule often begins at the age
of about three to about six months of age. The vaccine can
be administered in a single dose or in repeated doses by
administering a second booster injection approximately four
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to six weeks after the primary immunization and then
optionally giving a third booster injection another month
later. Thereafter, the vaccine can be given every three
months or annually depending on formulation and route of
administration. Concentration of the virus in the vaccine
may range, for example, from about 4 logs to about 9 logs
TCID 50/dose and a reasonable dosage may be given to the
horse in the amount of about 6 to about 7 logs TCID 50 /dose,
but should not contain an amount of virus-based antigen
sufficient to result in an adverse reaction or physiological
signs of viral infection. Methods are known in the art for
determining or titrating suitable dosages of active antigenic
agent based on the weight of the horse, concentration of the
antigen and other typical factors.
The vaccine of the invention can conveniently be administered orally, intranasally, intramuscularly, intrarectally,
transdermally (i.e., applied on or at the skin surface for
systemic absorption) or intradermally (i.e., injected or otherwise placed under the skin). Desirably, the routes of
administration are the oral, intranasal and intramuscular
routes. However, the oral and intranasal routes of administration are most preferred for inducement of strong local as
well as systemic immune responses.
When administered as a liquid, the present vaccine may
be prepared in the form of an aqueous solution, syrup, an
elixir, a tincture and the like. Such formulations are known
in the art and are typically prepared by dissolution of the
antigen and other typical additives in the appropriate carrier
or solvent systems. Suitable carriers or solvents include, but
are not limited to, water, saline, ethanol, ethylene glycol,
glycerol, etc. Optional additives are, for example, certified
dyes, flavors, sweeteners and antimicrobial preservatives
such as antibiotics or thimerosal (sodium ethylmercurithiosalicylate) where permitted by law. Such solutions may be
stabilized, for example, by addition of partially hydrolyzed
gelatin, sorbitol or cell culture medium, and may be buffered
by conventional methods using reagents known in the art,
such as sodium hydrogen phosphate, sodium dihydrogen
phosphate, potassium hydrogen phosphate, potassium dihydrogen phosphate, a mixture thereof, and the like.
Liquid formulations also may include suspensions and
emulsions that contain suspending or emulsifying agents in
combination with other standard co-formulants. These types
of liquid formulations may be prepared by conventional
methods. Suspensions, for example, may be prepared using
a colloid mill. Emulsions, for example, may be prepared
using a homogenizer.
Parenteral formulations designed for intramuscular injection and the like require proper isotonicity and pH buffering
to the level of equine body fluids and tissues. Isotonicity can
be appropriately adjusted with sodium chloride and other
salts as needed. Suitable solvents, such as ethanol or propylene glycol, can be used to increase the solubility of the
ingredients in the formulation and the stability of the liquid
preparation. Further additives that can be employed in the
present vaccine include, but are not limited to, dextrose,
conventional antioxidants and conventional chelating agents
such as ethylenediamine tetraacetic acid (EDTA). Parenteral
dosage forms must be sterilized prior to use.
An adjuvant, which may be administered in conjunction
with the vaccine of the present invention, is a substance that
increases the immunological response of the horse to the
vaccine. Since the strain of EHV-1 will be administered as
a live vaccine, an adjuvant is not necessarily required in all
formulations for achieving effective immunity. If it is desirable to include an adjuvant, for example, in a formulation
designed for the intramuscular route of administration, the

adjuvant may be administered at the same time and at the
same site as the vaccine, or at a different time as a booster.
Adjuvants also may advantageously be administered to the
horse in a mariner or at a site different from the manner or
site in which the vaccine is administered. Suitable adjuvants
include, but are not limited to, metabolizable oils of plant or
animal origin such as squalene (2,6,10,15,19,23-hexamor preferably,
ethyl-2,6,10,14,18,22-tetracosahexaene)
squalane (2,6, 10, 15,19,23-hexamethyl-tetracosane), nonionic block polymers or block copolymers based on ethylene
oxide and propylene oxide, for example, polyoxypropylenepolyoxyethylene block copolymers (also known as (poly
(ethylene oxide )-block-poly(propylene oxide)-block-poly
(ethylene oxide) or Poloxamer block copolymers NF) such
as Pluronic® (commercially available from BASF Corporation, Mount Olive, N.J.), saponin such as Qui! A (commercial name of a purified form of Quillaja saponaria,
available from Iscotec AB, Sweden and Superfos Biosector
a/s, Vedbaek, Denmark), ethylene/maleic copolymers such
as EMA-31 ® (a linear ethylene/maleic anhydride copolymer
having approximately equal amounts of ethylene and maleic
anhydride, having an estimated average molecular weight of
about 75,000 to 100,000, commercially available from Monsanto Co., St. Louis, Mo.), acrylic acid copolymers, acrylic
acid copolymer emulsions such as Neocryl® (an uncoalesced aqueous acrylic acid copolymer of acrylic acid and
methacrylic acid mixed with styrene, commercially available from Polyvinyl Chemicals, Inc., Wilmington, Mass.),
mineral oil emulsions such as MVP® (an oil-in-water emulsion oflight mineral oil, commercially available from Modem Veterinary Products, Omaha, Nebr.) or mixtures thereof
and the like. Other suitable adjuvants include, for example,
aluminum hydroxide (alum), immunostimulating complexes
(ISCOMS), cytokines (like IL-1, IL-2, IL-7, IL-12, IFN-a,
IFN-~, IFN-y, etc.), monophosphoryl lipid A (MLA),
muramyl dipeptides (MDP), aluminum potassium sulfate,
heat-labile or heat-stable enterotoxin isolated from Escherichia coli, cholera toxin or the B subunit thereof, diphtheria
toxin, tetanus toxin, pertussis toxin, Freund's incomplete or
complete adjuvant, etc. Toxin-based adjuvants, such as
diphtheria toxin, tetanus toxin and pertussis toxin may be
inactivated prior to use, for example, by treatment with
formaldehyde to make the corresponding toxoid. A particularly preferred adjuvant for use in the intramuscular formulations of the invention is the unique adjuvant Metastim® (a
registered trademark of Wyeth, Madison, N.J. comprising
squalane and Pluronic® L-121).
The equine vaccine of the invention may remain univalent
or be made multivalent and contain one or more additional
antigens to promote broad spectrum immunological activity.
The multivalent vaccine may include, but is not limited to,
other equine viruses such as, for example, killed EHV-4,
killed or live EHV-5, killed or live Equine Influenza Virus,
killed Eastern, Western, and Venezuelan Encephalomyelitis
viruses, inactivated West Nile Virus, or recombinant proteins
or recombinant vectors expressing proteins from these
viruses such as live canarypox vectors, live African Horse
Sickness virus or recombinant vectors expressing the African Horse Sickness virus antigens, and the like. In addition,
the multivalent vaccine may include, but is not limited to,
bacteria or bacterial toxoids acting as an additional antigen
such as tetanus toxoid, live or inactivated Streptococcus
equi, live recombinant vectors expressing S. equi antigens,
live Rhodococcus equi, live recombinant vectors expressing
R. equi antigens, leptospira antigens or live recombinant
vectors expressing leptospira antigens, Clostridum difficile
toxoid, live recombinant vectors expressing C. difficile anti-
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gens, etc. and protozoan antigens such as Sarcocystis neurona or Neospora hughesi and the like.
The new modified live viral vaccines ofthis invention are
not restricted to any particular method of preparation but can
be made by standard methods known in the art. To prepare
live, attenuated vaccines from the pathogenic virus, for
instance, the tissue culture adapted, live, pathogenic EHV-1
is attenuated (rendered nonpathogenic or harmless) by methods known in the art, typically through serial passages
through cell cultures. One could employ the techniques
described by C. T. Rosas et al., "Equine herpesvirus type 1
modified live virus vaccines: quo vaditis?" Review, Expert
Rev. Vaccines 5(1):119-131 (2006) that show how to generate RacH and Kentucky A (KyA) EHV-1 strains by continuous in vitro passages. Attenuation of the pathogenic
EHV-1 virus may also be done by gene deletions, gene
insertions or viral-producing gene mutations involving
many different genes such as, for example, the IR6 (inverted
repeat region 6), the gene regions encoding proteins gl, gE,
gM and gG, the thymidine kinase (TK) or immediate early
(IE) genes and 75 genes located in the Unique Short region
(US) as well as combinations thereof (C. T. Rosas et al., id.;
U.S. Pat. No. 6,225,111; U.S. Pat. No. 6,193,983; U.S. Pat.
No. 5,741,696; U.S. Pat. No. 5,731,188; U.S. Pat. No.
5,674,499 and U.S. Pat. No. 5,292,653; U.S. Published
Patent Application No. 2007/0166330; U.S. Published Patent Application No. 2004/0109873; U.S. Published Patent
Application No. 2004/063095; U.S. Published Patent Application No. 2003/0059934 and U.S. Published Patent Application No. 2003/198650; WO 2002/009750, among others).
As the terms are used in conjunction with the present
invention, a "low" pre-exposure level of herpesvirus-specific CTL precursors (i.e., the level of lymphocytes in the
blood possessing lethal activity against EHV-1) before the
horse is exposed to the herpesvirus means a measurement of
approximately 40 or lower, preferably, lower than 20 and
more preferably, less than 10 per 106 PBMC (equine peripheral blood mononuclear cells). The "high" levels of postinfection, leukocyte-associated viremia (i.e., the magnitude
of EHV-1 virus present in the blood of horses) refer to a
comparative measurement of approximately 10-fold or more
over an arbitrarily selected standard level (that is, the level
of EHV-1 present in the blood of horses four days after
infection with a non-neuropathogenic strain of the virus),
preferably, higher than 100-fold over the standard and more
preferably, greater than 1000-fold higher than the standard
level of the non-neuropathogenic virus. An effective infecting amount of a neuropathogenic strain of EHV-1 refers to
the amount of virus that produces a neurological infection in
the horse such as, for example, 107 PFU (plaque forming
units) of the neuropathogenic T953 strain ofEHV-1 (ORF30
G 2254), though it is contemplated that the effective infecting
amount is readily titrated by routine methods taking the
virulence of the virus, the weight of the horse, the age of the
horse, etc. into consideration. When a given value is
expressed as "approximate," "about" or similar terms, it
should be understood that the variation refers to acceptable
standard deviations of data in the field, for instance, ±5% of
the value, within six months of the specified ages of approximately 20 (i.e., can be six months younger than age 20) or
one year of age (can be six months over), or within a day less
than the one week old foal described herein.
For purposes of this invention, the neuropathogenic T953
strain of EHV-1 has been deposited under the conditions
mandated by 37 C.F.R. §1.808 and maintained pursuant to
the Budapest Treaty in the ATCC® (American Type Culture
Collection) Patent Depository, University Boulevard,

Manassas, Va. 20110-2209, U.S.A. Specifically, the EHV-1
T953 sample has been deposited in the ATCC on Jun. 19,
2008 and has been assigned ATCC® Patent Deposit Designation PTA-9273.
The following examples demonstrate certain aspects of
the present invention. However, it is to be understood that
these examples are for illustration only and do not purport to
be wholly definitive as to conditions and scope of this
invention. It should be appreciated that when typical reaction or experimental conditions (e.g., temperature, reaction
times, etc.) have been given, the conditions both above and
below the specified ranges can also be used, though generally less conveniently. The examples are conducted at room
temperature (about 23° C. to about 28° C.) and at atmospheric pressure. All parts and percents referred to herein are
on a weight basis and all temperatures are expressed in
degrees centigrade unless otherwise specified.
A further understanding of the present invention may be
obtained from the examples that follow below. These working examples are intended to illustrate the invention without
limiting its scope.
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Materials and Methods
Experimental Animals:
The experimental sample of animals used in these studies
consisted of 36 adult horse mares ranging in age from 4 to
28 years. Twenty-five of the experimental horses were
Thoroughbred broodmares donated to the M. H. Gluck
Equine Research Center (Department of Veterinary Science,
University of Kentucky, Lexington, Ky.) by local breeding
farms, while the remaining 11 mixed-breed mares were
provided from the experimental horse herd maintained by
the University of Kentucky's equine research farm. None of
the horses had been vaccinated for EHV-1 during the year
preceding their use in these studies. For experimental infection with EHV-1, the horses were kept as 3 randomly
assigned groups of 12 animals/group in half-acre, grassy lots
at the University's equine isolation facilities. Daily health
inspections, feeding and watering, preventive health activities (e.g., fly and parasite control, hoof care, vaccinations,
etc.), and handling and restraint for experimental procedures
were provided by farm personnel. Antipyretic, anti-inflammatory and analgesic medications were administered, as
prescribed by the IACUC-approved experimental, protocol,
by the principal investigator. Veterinary services (including
bladder catheterization, euthanasia, antibiotic therapy, etc.)
were performed, as needed, by experienced equine practitioners from a local veterinary practice. Following completion of the experimental procedures, the 30 equine survivors
of infection by EHV-1 were returned to the resident horse
population of the University's equine research farm.
Virus Strains:
A live, low-passaged, abortigenic strain of EHV-1 (Ky
T262) was used for intra-nasal inoculation of 12 of the
experimental horses. EHV-1 strain Ky T262 was isolated
from an aborted equine fetus during a large-scale outbreak
of herpesviral abortion ("abortion storm") on a commercial
Kentucky Thoroughbred breeding farm in 1975. Its ORF302254 genotype was determined by DNA sequencing using
routine methods to be A 2254 (J. Nugent et al., "Analysis of
equine herpesvirus type 1 strain variation reveals a point
mutation of the DNA polymerase strongly associated with
neuropathogenic versus non-neuropathogenic disease outbreaks," J Viral 80:4047-4060 (2006)).
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A live, low-passaged, neuropathogenic strain of EHV-1
(Ky T953) was used for intra-nasal inoculation of 24 of the
experimental horses. EHV-1 strain T953 was isolated from
the blood leukocytes of an adult horse that developed
quadriplegia during a multiple-case epizootic of EHV-1
myeloencephalopathy at a university equestrian center in
Ohio in 2003 (R. W. Henninger et al., "Outbreak of Neurologic Disease Caused by Equine Herpesvirus-1 at a University Equestrian Center," J Vet Intern Med 21:157-165
(2007)). Its ORF30-2254 genotype was determined by DNA
sequencing using routine methods to be G 2254 (J. Nugent et
al., "Analysis of equine herpesvirus type 1 strain variation
reveals a point mutation of the DNA polymerase strongly
associated with neuropathogenic versus non-neuropathogenic disease outbreaks," J Viral 80:4047-4060 (2006)).
Both strains of EHV-1 were originally isolated in monolayers of an equine dermal fibroblast cell line and propagated at low multiplicity of infection (moi=0.1) using the
same cell line for production of the virus stocks used for
horse inoculation.
Inoculation of Horses with EHV-1:
Preinfection blood and nasopharyngeal samples were
collected, and baseline rectal temperatures were recorded.
To initiate viral infection, each horse was inoculated intranasally with 107 plaque-forming units (PFU) of EHV-1 by
use of a fenestrated, 30.5 cm (12 inch) rubber catheter. The
course of infection was followed by daily monitoring of
clinical signs and rectal temperatures. Nasopharyngeal
secretions were collected daily for 7 days with 16-inch,
flexible, rayon-tipped swabs (for example, PROCTO
SWAB® commercially available from Henry Schein, Inc.,
Melville, N.Y.) and processed for virus isolation by inoculation of monolayers of equine dermal cells. Both coagulated and heparinized venous blood samples were collected
at 2, 4, 6, 8, 10, 12, 14 and 21 days post inoculation and
processed for serum and peripheral blood mononuclear cells
(PBMC), respectively.
The severity of clinical neurologic signs in the EHV-1
inoculated horses was graded using a simplification of the
scale described by Mayhew (I. Mayhew, "Evaluation of the
large animal neurological patient," Large Animal Neurology: A Handbook for Veterinary Clinicians 1989, Philadelphia, ed., Lea & Febiger, pp 3-69). The observed neurologic
deficits were categorized and recorded as either grade 1
(decreased tail muscle tone or toe-dragging), grade 2 (any
other walking gait abnormality or bladder atony ), or grade 3
(recumbency).
Preparation of DNA from Equine Peripheral Blood Mononuclear Cells (PBMC):
PBMC were purified by Ficoll-Hypaque centrifugation of
heparinized venous blood samples collected from horses
inoculated with EHV-1 (using, for example, Ficoll-Paque
PLUS® commercially available from GE Healthcare, Piscataway, N.J.) as previously reported (G. P. Allen and C. C.

Breathnach, "Quantification by real-time PCR of the magnitude and duration of leukocyte-associated viraemia in
horses infected with neuropathogenic versus non-neuropathogenic strains of equine herpesvirus-1," Equine Vet J
38:252-257 (2006)). For each test sample, RNA-free total
DNA was isolated from 5xl07 PBMCs using a commercial
kit designed for purification of genomic DNA from blood
leukocytes (for example, Wizard Genomic DNA Purification
Kit® commercially available from Promega, Madison,
Wis.). Purified DNA was dissolved in 200 µL of sterile water
and quantified via measurement of absorbance at 260 nm.
Real-Time PCR Quantification of EHV-1 DNA:
A real-time PCR assay was used for quantitative detection
of EHV-1 DNA present in peripheral blood mononuclear
cells of horses following experimental inoculation of EHV-1
in accordance with conventional techniques previously
described (G. P. Allen and C. C. Breathnach, 2006, id). The
assay was performed using TaqMan® detection chemistry
(commercially available from Applied Biosystems, Foster
City, Calif.) and the 7500 Real-Time PCR system (using, for
example, 7500 SDS Software®, ver. 1.3.1, commercially
available from Applied Biosystems, Foster City, Calif.). The
real-time amplification primers and TaqMan® fluorescent
detection probes used are listed in the below Table 1. For
each DNA sample, triplicate real-time PCR reactions were
run, each containing 1 µg of PBMC DNA in 25 µL of
complete PCR reaction mixture with 900 nM primers
designed to amplify a 60 bp fragment of the EHV-1 glycoprotein B (gB) gene, and 250 nM fluorescent (5'-FAM)
TaqMan® probe for real-time detection of the amplified gB
sequence. As an endogenous control for normalization of
sample-to-sample variations in the amount of target DNA
added to the reaction wells, 3 different replicates of each
sample were run with the gB primer/probe set replaced with
a primer pair and fluorescent probe for detection of the
equine ~-actin gene sequence (Table 1). Amplification
parameters consisted of an initial denaturation step of 95° C.
for 10 minutes followed by 45 cycles of 95° C. for 15
seconds and 60° C. for 1 minute. Quantitative comparison
and statistical analysis of the results were performed by
7500 SDS Software® (ver. 1.3.1, commercially available
from Applied Biosystems, Foster City, Calif.), using the
Delta-Delta-Cr relative quantification method for expressing
observed quantitative differences in levels of EHV-1 DNA
(K. J. Livak and T. D. Schmittgen, "Analysis ofrelative gene
expression data using real-time quantitative PCR and the
Delta-Delta Cr method," Methods 25:402-408 (2001)). The
quality control parameters (specificity, sensitivity, dynamic
range, efficiency of amplification) and characteristics of the
calibrator DNA for the real-time PCR assay have been
described previously (G. P. Allen and C. C. Breathnach,
2006, supra).
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TABLE 1
Real-time PCR oliqo primers and fluorescent detection probes used in the study

Primer/probe

Sequence ( 5' to 3')

Target DNA

EHVlGB-JNlF

CTG CCC CTG GAG GTG TAC (SEQ ID NO, 1)

EHV-1 gB

EHVlGB-JNlR

TTG CGG CGC TGT ATT TCG (SEQ ID NO, 2)

EHV-1 gB

EHVlGB-JNlMl

FAM-CAC CGG CCT GCT AGA CT-NFQ
EHV-1 gB
(SEQ ID NO, 3 with minor groove binder adduct)

EQBACTINIS-JN3F

CCC CGA GGC CCT CTT C (SEQ ID NO, 4)

Equine 13-actin
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TABLE 1-continued

Real-time PCR oligo primers and fluorescent detection probes used in the study

Primer/probe

Sequence (5' to 3')

Target DNA

EQBACTINIS-JN3R

GA GTT GAA GGT AGT TTC GTG GAT (SEQ ID NO, 5)

Equine ~-actin

EQBACTINIS-JN3Ml FAM-CCC TCC UC CTG GGC ATG-NFQ
Equine ~-actin
(SEQ ID NO, 6 with minor groove binder adduct)
FAM
NFQ

=
=

6 carboxyfluorescein reporter fluoroprobe;
non-fluorescent quencher moiety

Determination of CTLp Frequency:
Estimation of the frequency of EHV-1 specific CTL
precursors (CTLp) present in the peripheral blood circulation of horses was done by a limiting dilution microculture
system developed by O'Neill et al. (T. O'Neill et al.,
"Determination of equid herpesvirus I-specific, CDS+, cytotoxic T lymphocyte precursor frequencies in ponies," Vet
Immunol & Immunopathol 70:43-54 (1999)). Seven, twofold dilutions of PBMC responder cells were cultured in
vitro with autologous, stimulator PBMCs that expressed
EHV-1 antigens. Stimulator PBMCs were generated by
infection with 10 PFU ofEHV-1 (Army-183 strain) per cell
for 90 minutes followed by a 30-minute treatment at 37° C.
with 25 µg/mL mitomycin-C to block proliferation of the
stimulator cells during culture. Twenty-four, 200-µL replicates of each responder cell dilution were co-cultivated in
96-well round-bottomed microplates with 50,000 stimulator
PBMC which functioned as antigen-presenting cells and
feeder cells for support of single-cell clonal growth of
CTLp. After 10 days of incubation at 37° C. in the presence
of 10 Units ofrecombinant human interleukin-2 (rH-IL-2),
the induction cultures were assayed for cytolytic activity
against chromium-51 (Cr-51) labeled, EHV-1 (Amy-183
strain) infected lymphoblast targets (pokeweed mitogen
stimulated PBMC), using standard techniques as described
by O'Neill et al. (1999, id.). The amount of Cr-51 released
into each culture well was determined after a 4-hour incubation with 10,000 target cells by counting 200-µL of cell
free supernatant from each well in a gamma counter. Spontaneous Cr-51 release by target cells was determined in wells
without responder cells, and maximal Cr-51 release was
measured in wells containing 0.05% NP-40 detergent. A
culture well was scored as lysis-positive if the supernatant
counts per minute (cpm) ofCr-51 exceeded by >2-fold the
mean spontaneous Cr-51 release. Frequencies of CTLp in
the blood of each horse were calculated by using the
statistical evaluation software program of Strijbosch et al.
(L. W. Strijbosch et al., "Limiting dilution assays: Experimental design and statistical analysis," J Immunol Meth
97:133-40 (1987)). The frequencies ofCTL precursors specific for EHV-1 are expressed as CTLp per million responder
PBMC.
Determination of Serum Neutralizing Antibody Titer:
Measurement of EHV-1 serum neutralizing antibody
(SNA) titers was performed by a standard microneutralization assay described previously (C. C. Breathnach et al.,
"The mucosa! humoral immune response of the horse to
infective challenge and vaccination with equine herpesvirus-1 antigens," Equine Vet J 33:651-657 (2001)).
Statistical Analysis:
Differences observed between experimental groups of
horses in two categorical variables (e.g., age category and
occurrence of neurologic disease or virus strain and occurrence of neurologic disease) were tested for statistical sig-
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nificance by analysis of 2x2 contingency tables by Fisher's
exact test of independence. Significance of differences
between experimental horse groups in numerical variables
(e.g., viremic load or CTLp frequency) was tested by
one-way analysis of variance. The significance of an
observed linear relationship between two measured numerical variables (e.g., viremic load and CTLp frequency or
viremic load and SNA titer) was examined by linear least
squares regression analysis. Statistically significant relationships between one categorical variable (e.g., occurrence of
disease) and one numerical variable (e.g., pre-exposure
CTLp frequency or pre-exposure SNA titer) were established by logistic regression analysis.
Example 1
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Relationship Among CTLp Frequency, EHV-1
Viremia and Development of Neurologic Disease
To summarize the study design, 36 horse mares were used
for all of the studies described herein. The 24 elderly horses
(>20 years) were randomly assigned to either of two experimental groups of 12 horses each (groups A and B). The
remaining 12, younger horses (<15 years) comprised experimental group C. All 24 animals in groups A and C were
inoculated with 107 PFU (plaque forming units) of a neuropathogenic strain ofEHV-1 (T953). The 12 group B horses
were inoculated with 107 PFU of a non-neuropathogenic
strain ofEHV-1 (T262). Statistical comparisons ofresponse
variables (e.g., development of neurologic signs, magnitude
of viremia, etc.) were made between experimental horse
groups that differed in one or more predictor variables (e.g.,
challenge strain of EHV-1, age-category, breed, pre-exposure levels of CTLp or SNA titers, etc.).
Nine of the 24 horses inoculated with the neuropathogenic
strain of EHV-1 (Ky T953) developed clinical signs of
central nervous system disease. Grade 2 neurologic deficits
were present in three of the horses, while the remaining six
animals displayed grade 3 neurologic signs. A scatter plot
graphical summarization of the relationship between the two
numerical variables "post-infection viremic load" (y axis)
and "pre-exposure CTLp frequency" (x axis) for the 24
EHV-1 inoculated horses is shown in FIG. 1 (open and filled
circles). The nine horses that developed clinical signs of
neurological disease (categorical variable) following EHV-1
challenge infection are indicated on the plot by the open
circles. The differences between the two age groups of mares
in their mean magnitude of EHV-1 viremia are significant at
P=2:0.05 for after inoculation days 4 through 10. Because the
appearance of the scatter plot indicated a fairly strong linear
relationship between the individual values of the two parameters "pre-infection CTLp frequency" and "post-infection
viremic load," a linear regression line (solid line) was fitted
to the data points using the least squares computational
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method (for example, SigmaStat® 3.1 statistical analysis
software commercially available from SYSTAT Software,
Inc., Point Richmond, Calif.).
The linear relationship between the two numerical values
may be summarized by the slope-intercept equation, y=a+
bx, where "a" is they-intercept and the slope is represented
as the number "b" value multiplied by the "x" value to
obtain where the line crosses the y-axis. In terms of the
present invention, "peak viremic load" (y value)=2.97 (y-intercept a value)+-0.027 (slope b value) X "pre-infection
CTLp frequency" (x value). The correlation coefficient
statistic r between the two numerical variables was -0.79.
Simply stated, the regression line relationship can be reliably used to predict the magnitude of viremia following
EHV-1 infection of a horse and its subsequent likelihood for
development of neurologic signs, given the pre-infection
frequency of the horses's circulating, virus-specific CTLp.
Using the statistic, r 2 , as a measure of scatter of the observed
data points from the regression line, 62% of the value of the
post-exposure magnitude of EHV-1 viremia in an exposed
horse can be accounted for by the value of the variable
"pre-exposure frequency of EHV-1 specific CTLp." The
computed statistical probability (P value) that no straightline relationship exists between the numerical values of
"pre-exposure CTLp" and "post-exposure viremic load" was
P=<0.001.
Of particular clinical significance was the observation that
all nine horses that developed neurologic signs (open circles,
FIG. 1) after inoculation with a neuropathogenic strain of
EHV-1 possessed the combination of low CTLp frequency
and high viremic load. Statistical significances of the
observed differences in the mean viremic loads between the
two age categories of horses were calculated by one way
analysis of variance.

greater risk for post-exposure development of EHV-1 neurologic signs in elderly (>20 years) horses than in horses less
than 15 years of age.
The data were also analyzed for a breed effect on the
development of post-infection EHV-1 neurological disease
in the 24 horses. The proportion of horses that developed
clinical neurological signs in the two breed categories of
horses (Thoroughbred and mixed-breed mares) was not
significantly different than expected from random occurrence (P=0.41).
To explore the biological basis underlying the greater
susceptibility of aged (elderly) horses to EHV-1 myeloencephalopathy, the magnitude of post-inoculation cell-associated viremia that developed in the two age-categories of
mares was measured and compared (FIG. 2). Statistical
significances of the observed differences in the mean viremic loads between the two age categories of horses were
calculated by one-way analysis of variance. The differences
between the two age groups of mares in their mean magnitude of EHV-1 viremia were significant at P=s0.05 for
post-inoculation days 4 through 10. The magnitude of
EHV-1 viremia was greater in the elderly category of mares
at all times post-infection, with levels ranging from 10- to
200-fold higher than in the younger mares.

5

10

15

20

25

Example 3

30

35

Example 2
Relationship Between Age of EHV-1 Exposed
Horse and Development of Neurological Disease
The association between "mare age-category" and postinoculation development of "clinical signs of EHV-1 neurological disease" was examined. The null hypothesis was
that, following inoculation of mares of different age categories with neuropathogenic EHV-1, the incidence of neurological disease would be the same in young (<15 years) and
elderly (>20 years) age categories of horses.
To test the hypothesis, 12 mares belonging to each of the
two age groups (<15 years or >20 years) were inoculated
intranasally with 107 PFU (plaque forming units) of a
neuropathogenic strain of EHV-1 (T953) and observed twice
daily for 3 weeks for neurologic signs. Only one mare from
the <15 y age category exhibited post-inoculation neurologic signs consisting of hindlimb incoordination and dribbling of urine (grade 2) that necessitated the placement of an
indwelling urinary catheter. The mare made a full recovery
after 2 weeks. In contrast, 8 of the 12 EHV-1 inoculated
elderly mares developed clinical signs of neurologic disease.
Two of the neurologically affected old mares were ataxic
only or ataxic with urinary bladder atony (grade 2), while the
remaining 6 developed lateral recumbency (grade 3) and
were euthanized.
Using Fisher's exact test for analysis of the experimental
data, the P-value statistic was 0.009, indicating that the null
hypothesis can be rejected and that there is a significantly
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Relationship Between EHV-1 Genotype and
Post-Exposure Development of Equine Neurologic
Disease
To test the hypothesis that ORF30 G 2254 strains ofEHV-1
pose a greater risk than A 2254 strains for causing EHV-1
myeloencephalopathy, 12 elderly (>20 years) mares were
inoculated intranasally with 107 PFU (plaque forming units)
of the abortigenic T262 strain of EHV-1 (ORF30 A 2254) and
12 other elderly mares were inoculated with 107 PFU of the
neuropathogenic T953 strain ofEHV-1 (ORF30 G 2254 ). All
24 of the mares possessed low pre-inoculation levels of
EHV-1 specific CTLp (<40 per 106 PBMC). While none of
the aged horses exposed to the abortigenic strain (T262) of
EHV-1 exhibited neurologic signs, 8 of the 12 elderly horses
exposed to the neuropathogenic strain (T953) of the herpesvirus developed clinical neurological disease (two grade 2
and six grade 3 neurologic cases).
The virological basis for the differing levels of neuropathogenicity possessed by the two ENV-1 genotypes was
explored by comparison of the magnitude of leukocyteassociated viremia exhibited by the two experimental treatment groups of horses (FIG. 3). The differences in the mean
magnitude of EHV-1 viremia resulting from inoculation
with the two genetic strains of EHV-1 are significant at
P=s0.05 for post inoculation days 4 through 12.
At all sampling times following virus inoculation, the
circulating viremic load was significantly greater in the
group of 12 horses exposed to the ORF30 G 2254 genotype
(T953) of EHV-1.
Example 4
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Relationship Between Pre-Exposure SNA Titer to
EHV-1 and Post-Exposure Development of Equine
Neurologic Disease
65

For the 24 horses inoculated with the neuropathogenic
strain of EHV-1 (T953), quantitative measurements of
EHV-1 specific, serum neutralizing antibody (SNA) present
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of virus challenge were done by microneutral1zat10n assays (FIG. 4). The correlation coefficient r
between the two plotted variables is 0.31. The statistical
probability (P value) that no linear relationship exists
between pre-exposure SNA titer and magnitude of postexposure EHV-1 viremia is 0.144. No significant association
was detected between pre-exposure SNA titers and the
magnitude of post-infection EHV-1 viremia. Likewise, no
significant correlation between resistance of horses to
EHV-1 neurological disease and pre-exposure levels of
serum neutralizing antibody against the virus could be
demonstrated.

In the foregoing, there has been provided a detailed
description of particular embodiments of the present invention for purpose of illustration and not limitation. It is to be
understood that all other modifications, ramifications and
equivalents obvious to those having skill in the art based on
this disclosure are intended to be included within the scope
of the invention as claimed.
What is claimed is:
1. An equine vaccine comprising a nontoxic, physiologically acceptable carrier and an immunogenic amount of a
live, attenuated neuropathogenic strain of EHV-1 comprising the EHV-1 strain T953, wherein the neuropathogenic
strain is attenuated by serial passages and the vaccine
protects a horse from a neurologic form of EHV-1 disease.
2. The equine vaccine according to claim 1, further
comprising an antigen selected from the group consisting of:
EHV-4, EHV-5, Equine Influenza Virus, Eastern Encephalomyelitis Virus, Western Encephalomyelitis Virus, Venezuelan Encephalomyelitis Virus, West Nile Virus, African
Horse Sickness Virus, tetanus toxoid, Streptococcus equi,
Rhodococcus equi, leptospira, Clostridum difficile, Sarcocystis neurona, Neospora hughesi, a recombinant protein or
a recombinant vector expressing a protein derived therefrom
and a combination thereof.
3. The equine vaccine according to claim 1, further
comprising an adjuvant.
4. The equine vaccine according to claim 3, wherein the
adjuvant comprises squalane and a polyoxypropylene-polyoxyethylene block copolymer.
5. A method of protecting a horse against neurologic
disease or viral infection caused by a neuropathogenic strain
of EHV-1 comprising administering to the horse in need of
protection an immunologically effective amount of the
equine vaccine according to claim 1.
6. The method according to claim 5, which comprises
administering the vaccine orally, intranasally, intramuscularly, intrarectally, transdermally or intradermally to the
horse.
7. The method according to claim 5, further comprising
administering an adjuvant immediately before, during or
after the equine vaccine is administered or alternatively
administering the equine vaccine further cont~ining an adju~
vant.
8. The method according to claim 7, wherein the adjuvant
comprises squalane and a polyoxypropylene-polyoxyethylene block copolymer.
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Example 5
Determination of Immune Protection Against
EHV-1 Neurologic Disease Using Experimental
Horse Model of Present Invention
Twenty-four elderly horses comprised the experimental
animal study sample. Twelve horses randomly selected from
the group were vaccinated by intranasal inoculation with a
live, non-neuropathogenic abortion isolate of Ky T262
EHV-1. The remaining 12 horses were housed in separate
facilities and sham-vaccinated by intranasal inoculation of
culture medium from uninfected tissue culture cells.
Ninety days after vaccination or sham-vaccination all 24
experimental horses were challenged by intranasal i~oculation with the neuropathogenic isolate ofEHV-1 (T953). The
challenged horses were evaluated daily for fever, nasal
discharge and neurologic dysfunction. Serum samples and
PBMC were collected for 21 days post-challenge for determination of antibody titers and quantitative levels of EHV-1
viremia. As a measure of CTL activity, PBMC samples
collected from each experimental horse were also analyzed
for the presence of EHV-1 specific, IFN-gamma expressing
cytotoxic CDS+ T-lymphocytes.
The results of the vaccination-challenge study were analyzed by Fisher's exact test which identified a statistically
significant reduction in the frequency of post-challenge
EHV-1 neurologic disorders in the vaccinated group of
horses and validated the utility of the vaccination-challenge
model. Surprisingly, the live, non-neuropathogenic isolate of
EHV-1 (ORF30 A 2254 genotype) was able to afford protection. against EHV-1 neurologic disease. In sum, this vaccinat10n-challenge study design finds use in the identification
of live vaccine candidates that protect against neurological
disease.
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